Eisai的抗癌药物tazemetatat在日本因罕见的软组织癌症而获得孤儿地位。 Eisai's anticancer drug tazemetostat gets orphan status in Japan for a rare soft tissue cancer.

Eisai的抗癌药物 tazemetostat在日本被指定为孤儿药物, 治疗一种罕见的软组织癌症, Eisai's anticancer drug tazemetostat has been given orphan drug designation in Japan for treating a rare form of soft tissue cancer called INI1-negative epithelioid sarcoma. 这类癌症影响到日本不到50,000人,治疗选择有限,导致大量医疗需求未得到满足。 This type of cancer affects fewer than 50,000 people in Japan and has limited treatment options, leading to significant unmet medical needs. Eisai目前正在第二阶段临床试验中测试该病的tazemetostat。 Eisai is currently testing tazemetostat in a Phase II clinical trial for this condition.